Alexey Terskikh

Title: Alexey Terskikh: Innovator in Cancer Diagnostics

Introduction

Alexey Terskikh is a notable inventor based in Lausanne, Switzerland. He has made significant contributions to the field of cancer diagnostics through his innovative work on recombinant glycoproteins. His research focuses on improving the accuracy and effectiveness of diagnostic tests for neoplastic diseases.

Latest Patents

Terskikh holds a patent for "Carcino-embryonic antigen derivatives lacking the carboxyl terminal end." This invention provides recombinant CEA glycoproteins and methods for their production. The recombinant CEA glycoproteins lack the C-terminal 26 amino acids found in natural CEA. They are characterized by being free from cross-reactive CEA-like antigens, antigenically indistinguishable from the soluble form of CEA shed from tumor cells, and devoid of ethanolamine and additional amino acids typically attached to natural CEA. The invention also includes a DNA encoding the recombinant CEA glycoprotein and recombinant vectors capable of directing the expression of this DNA in compatible host cells. These glycoproteins can be integrated into test kits for determining the presence of tumor cells in body fluid samples.

Career Highlights

Alexey Terskikh is associated with Roche Diagnostic Systems, Inc., where he continues to advance his research in cancer diagnostics. His work has the potential to significantly impact the early detection and treatment of cancer, improving patient outcomes.

Collaborations

Terskikh has collaborated with notable colleagues such as Andre Pelegrin and Jean-Pierre Mach. Their combined expertise contributes to the innovative research and development of diagnostic tools in the medical field.

Conclusion

Alexey Terskikh is a pioneering inventor whose work in recombinant glycoproteins is shaping the future of cancer diagnostics. His contributions are vital for enhancing the accuracy of diagnostic tests, ultimately benefiting patients worldwide.